Surgery Websites
Department of Surgery »  Faculty »  Adult Cardiothoracic Surgery »  Bhairavi Tolani, Ph.D., M.S.
Bhairavi Tolani, Ph.D., M.S.

Bhairavi Tolani, Ph.D., M.S.

Assistant Professor
Division of Adult Cardiothoracic Surgery

Contact Information

Open Popup
  • University of Southern California, Los Angeles, California, Ph.D., Molecular Biology, 2013
  • Hood College, Frederick, Maryland, M.S., Biomedical Sciences, 2007
  • Hood College, Frederick, Maryland, B.A., Biochemistry, 2004
  • Postdoctoral Fellow, Stanford Research Institute, Menlo Park, 2013-2014
  • Postdoctoral Fellow, UCSF Thoracic Oncology Lab, 2014-2015
  • Thoracic Oncology Program
  • Thoracic Oncology Laboratory
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Department of Surgery
  • Epigenetics & Virology
  • Hedgehog and other developmental pathway signaling
  • Small molecule inhibitors and biologics
  • Stem cell biology & cancer stem cells
  • Targeted therapies for lung and other cancers

Bhairavi (Vivi) Tolani, Ph.D., M.S. is member of the Thoracic Oncology Lab, having initially joined the lab in June 2014 as a postdoctoral scholar. Dr. Tolani's research is focused on developing targeted therapies, small molecule inhibitors and biologics, for lung cancer.

Dr. Tolani provides research mentorship and supervision to surgical residents in UCSF's program as well as visiting thoracic surgeons, technicians and high school students. Prior to beginning her second postdoctoral fellowship  at UCSF, she worked on cancer immunology as a postdoctoral fellow at the Stanford Research Institute.

Dr. Tolani earned her Ph.D. in Molecular Biology from the University of Southern California's Keck School of Medicine under the mentorship of Preet Chaudhary M.D., Ph.D., chief of the Nohl Division of Hematology and Blood Diseases at Keck. A self-starter, she convinced the lab to undertake a new project involving small molecule BET epigenetic inhibitor drugs to target blood cancers in collaboration with Dr. James Bradner at Harvard's Dana Farber Cancer Institute. Her doctoral research resulted in 5 peer-reviewed publications, and presentations at The American Society of Hematology (ASH) and The Gordon Research Conference.

  • Hellman Fellows Fund, UCSF, 2019
  • UCSF RAP Pilot Award, UCSF, 2019
  • Keller Entrepreneurship Fellow, UC Davis, 2014
  • "Best Poster" at Biology Interdepartmental Graduate Symposium, University of Southern California, 2010
  • "Outstanding Poster Presentation" at the Spring Research Festival, The National Cancer Institute, 2004

Over the past 10 years, Dr. Tolani's cancer research experience has been diverse including breast cancer, ovarian cancer, cervical cancer, lung cancer and hematological malignancies spanning academia, industry and the National Institutes of Health. Prior to graduate school, she worked at 3 biotechnology companies [Invitrogen Life Technologies, Lonza, & Digene (Qiagen)] for 3 years. While at Digene, she contributed to the development of a test to detect cervical cancer in women. Her work in industry earned her "Job Excellence" and "No Matter What it Takes" awards at Invitrogen Life Technologies and Lonza respectively. Concurrently she earned her M.S. in Biomedical Sciences while conducting her thesis research on cancer stem cells and the Hedgehog pathway in breast cancer at the National Cancer Institute.

From a total of 14 publications
  1. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Bhairavi Tolani, Ph.D., M.S.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.
  1. Gopalakrishnan R, Matta H, Tolani B, Triche T, Bradner JE, Chaudhary PM (2014) Immunomodulatory Drugs are Efficacious against Primary Effusion Lymphoma by Targeting IZKF1, IRF4 and MYC in a CRBN-Dependent Manner and are Synergistic with BRD4 Inhibitors. [ASH poster abstract]
  2. Tolani B, Ly J, Dangaj D, Powell DJ Jr, Danet-Desnoyers G, et al.. (2014) Characterization of the Tumor Microenvironment of a Humanized Mouse Model of ovarian cancer after treatment with anti-B7-H4 recombinant Antibodies. [AACR poster abstract published online]
  3. Tolani B, Goodman M (2010) Binding & Deamination by Activation-Induced Cytidine Deaminase (AID) [Gordon Research Conference poster]


Site Directory